FATE

NASD Fate Therapeutics, Inc.
Sep 29, 2026 · 4:57 PM ET LAST TRADE Market Closed

$2.42 ↑ +0.04 (+1.68%) Trading Up from the previous close of $2.38, and at the day’s high of $2.41

YTD change
+146.29%
vs 20-day SMA
-0.27%
vs 200-day SMA
+32.44%

Price ranges

Previous day
$2.27 $2.42
open $2.30 close $2.38
+$0.08 (+3.48%)
Today
$2.29 $2.41
open $2.37 now $2.42
+$0.05 (+2.11%)
Past week
$2.27 $2.63
from $2.53 now $2.42
-$0.11 (-4.35%)
Past month
$2.27 $2.69
from $2.43 now $2.42
-$0.01 (-0.41%)
This year
$0.97 $3.23
from $0.98 now $2.42
+$1.44 (+146.29%)

Price & Performance

+1.25 (+110.62%) / 6M

$0.9716$1.74$2.50$3.27Mar 30Jun 29Sep 28

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Neutral
  • The stock is 98.0% away from all-time highs of $121.16
  • FATE is up 146% since the beginning of the year
  • FATE is up 142% over the past 12 months
  • FATE is down 0% over the past 1 month
  • 8% of all FATE investors are betting against FATE

FATE reads neutral: price sits above one of the two key moving averages, the 12-month move is +138.0%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.25
Earnings momentum +7.7% Quarterly EPS growth
Quarterly change +7.7%

Valuation

P/E ratio N/A
Enterprise value $208.5M
Beta 3.98

Balance sheet & scale

IncomeN/A
Revenue$6.5M
Cash$153.8M
Debt$75.7K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $290.0M

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Competitor comparison

TickerCompany PriceChange
REGN Regeneron Pharmaceuticals, Inc. $752.25 -4.54%
IQV IQVIA Holdings Inc $270.97 +0.22%
CRL Charles River Laboratories International, Inc. $294.59 +0.60%
ICLR ICON Plc $175.57 +1.88%
MDGL Madrigal Pharmaceuticals, Inc. $517.04 +0.09%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.